Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Germany struggles to shift AstraZeneca vaccine doses

Thu, 25th Mar 2021 16:19

* Germany has administered just 60% of delivered AZ
doses-RKI data

* Merkel says "not ok" if vaccination appointments going
unused

* Scepticism, patchy state rollout, data monitoring play a
role

By Caroline Copley

BERLIN, March 25 (Reuters) - Berlin pensioner Gerhard
Schaeufele decided he'd prefer to wait 10 days and cross the
city for a shot of the BioNTech/Pfizer
coronavirus vaccine, rather than accept an AstraZeneca vaccine
in two days' time at his local centre.

"A week ago, maybe I would have taken AstraZeneca," the
72-year-old retired university arts teacher told Reuters,
describing himself as someone who follows his gut feeling.

But he said the recent back-and-forth over the vaccine's
efficacy and safety put him off.

AstraZeneca says its vaccine is safe and effective, citing
extensive trial data. Millions of doses have been safely
administered around the world and the EU's medicines watchdog
and the World Health Organisation have reaffirmed it safe. Most
of the states which briefly halted its use, including Germany,
have resumed giving the shot.

However, Schaeufele's hesitancy towards AstraZeneca's shot
underscores the challenge Berlin faces as it seeks to ramp up
its sluggish vaccine rollout while contending with a third wave
of the pandemic, driven by more infectious virus variants.

It's an issue faced by governments across the European Union
as they seek to get their vaccine rollouts back on track. A
third of Danes say they won't accept the Anglo-Swedish shot,
while some in France remain sceptical.

According to data from the Robert Koch Institute (RKI) of
infectious diseases, around 2.1 million or 60 percent of the
doses of AstraZeneca's vaccine to arrive in Germany have been
used. By comparison 83% of BioNTech/Pfizer vaccines have been
used.

A survey of Germany's states, who are responsible for the
vaccine rollout, suggests the low take-up is attributable in
part to organisational bottlenecks as well as people's
uncertainty over the AstraZeneca vaccine.

Chancellor Angela Merkel, 66, who is facing growing
criticism over her handling of the pandemic, has said she would
herself accept the AstraZeneca vaccine when her turn came.

She told the Bundestag on Thursday that it was "not ok" that
appointments were going unused.

In Berlin, the AstraZeneca shot is available at former
airports Tegel and Tempelhof, and appointments were available to
those eligible as soon as this coming weekend when Reuters
checked on Thursday.

At Berlin's four other centres, which administer BioNTech
and Moderna, no time slots were available within the
next month.

BUREAUCRATIC BACKLOGS

In Bremen, the country's smallest state, 80% of its
AstraZeneca doses have been administered with local officials
saying they were quick to offer appointments to teachers and
daycare staff once the priority list was amended on Feb. 24.

In Saxony by contrast, less than 30% of its AstraZeneca
doses have so far been used. The state has not yet made the
vaccine available in hospitals although medical staff would be
eligible, according to a person working on the rollout.

A spokeswoman for the health ministry in the state of
Saxony-Anhalt said the initial recommendation that the
AstraZeneca shot only be given to those under 65 had acted as a
hindrance, citing "greater organisational effort" to arrange
appointments for those in the next priority group.

Meanwhile, in Mecklenburg-Vorpommern, shots were delayed
after 12,200 AZ doses had to be put in "quarantine" for a week
due to an error in the cold chain of the delivery company.

One of the biggest hurdles for the rollout has been
inconsistent deliveries and supply constraints. But this is set
to change with deliveries of around 15 million doses in total of
all three approved vaccines in April.

Ruth Waldmann, health spokesperson for the Social Democrats
in the Bavarian state parliament, said it was time to "fire up
the vaccination turbo" by bringing on board family doctors.

Germany plans to supply doctors with a million vaccines per
week from April rising to three million by the end of the month,
and hopes this will add more firepower and flexibility to its
rollout.

Family doctors could easily inoculate 2.5 million people per
week if each practice does just 10 shots per day, according to
the national association.
(Reporting by Caroline Copley
Additional reporting by Michael Nienaber, Thomas Escritt and
Christina Amann
Editing by Alexandra Hudson)

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.